Company: HURA
Filing Date: 2025-09-18
Form Type: S-1/A
Source: 0001193125-25-207395
Chunk: 291

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-09-18
Form: S-1/A
Chunk 291
---
 |   |
| Net proceeds from the issuance of shares - ATM                             |     |      | 7 |     |                              |  2,476 |   |     |      |      — |   |
| Series A Preferred cash dividend                                           |     |      | 6 |     |                              |     (4 | ) |     |      |     (4 | ) |
| Net cash provided by financing activities                                  |     |      |   |     |                              |  2,577 |   |     |      |  1,856 |   |
| Decrease in cash and cash equivalents                                      |     |      |   |     |                              |   (877 | ) |     |      | (6,906 | ) |
| Cash and cash equivalents - beginning of period                            |     |      |   |     |                              |  1,535 |   |     |      | 11,780 |   |
| Cash and cash equivalents - end of period                                  |     |      |   |     |                              |    658 |   |     |      |  4,874 |   |
| Supplementary information(note 8)                                          |     |      |   |     |                              |        |   |     |      |        |   |

The accompanying notes are an integral part of these condensed consolidated interim financial statements. F-5 2

Kintara Therapeutics, Inc. Notes to Condensed Consolidated Interim Financial Statements (Unaudited) December 31, 2023 (expressed in US dollars and in thousands, except par value and per share amounts, unless otherwise noted)

| 1 | Nature of operations, corporate history, and going concern and management plans |

Nature of operations

Kintara Therapeutics, Inc. (the “Company”) is a clinical-stage drug development company with a focus on the development of novel cancer therapies for patients with unmet medical needs. The Company is developing one late-stage therapeutic - REM-001 for cutaneous metastatic breast cancer (“CMBC”). In order to accelerate the Company’s development timelines, it leverages existing preclinical and clinical data from a wide range of sources. The Company may seek marketing partnerships in order to potentially offset clinical costs and to generate future royalty revenue from approved indications of its current and future product candidates.

Corporate history

The Company is a Nevada corporation formed on June 24, 2009, under the name Berry Only, Inc. On January 25, 2013,